Angela Colbers - Concepedia

Author

Angela Colbers

Also Known As

A Colbers, A. Colbers, Alexandra Coelho, Angela Colbers, Angela P. Colbers, Angela P. H. Colbers, Angela P.H. Colbers, Angela PH Colbers, Colbers, A, David Burger

125

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center Radboud Institute for Molecular Life Sciences Erasmus MC Hospital Universitari Germans Trias i Pujol

About

Angela Colbers is an author at Radboud University Nijmegen specializing in medicine, pharmacotherapy, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	202
2	Pharmacology	2	2	48
3	Public Health	1	1	117
4	Biochemistry	1	1	30
5	Obstetrics	1	1	117

Angela Colbers

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial Kenneth Kintu, Thokozile R. Malaba, Jesca Nakibuka, The Lancet HIV Treatment And PreventionDolutegravir Versus EfavirenzReproductive HealthAntiviral TherapyGynecology	2020	117
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children Anna Turkova, Ellen White, Avy Violari, UCL Discovery (University College London)	2021	102
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women Angela Colbers, David Hawkins, Andrea Gingelmaier, AIDS	2012	74
Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1–Infected Women Stein Schalkwijk, Angela Colbers, Déborah Konopnicki, Clinical Infectious Diseases	2017	71
Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy Maren I. Blonk, Angela Colbers, Carmen Hidalgo-Tenorio, Clinical Infectious Diseases	2015	61
Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients Vincent J. Lempers, Jeroen Schouten, Nicole Hunfeld, Antimicrobial Agents and Chemotherapy	2015	57
Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling Stein Schalkwijk, Aaron O. Buaben, Jolien J. M. Freriksen, Clinical Pharmacokinetics	2017	50
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study Thokozile R. Malaba, Irene Nakatudde, Kenneth Kintu, The Lancet HIV	2022	50
Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy Angela Colbers, Rick Greupink, Carlijn H. C. Litjens, Clinical Pharmacokinetics	2015	46
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial Pauline Bollen, Cecilia L. Moore, Hilda Mujuru, The Lancet HIV	2020	46

Page 1